Medication doses are changed over time throughout hormone treatments. This is based on carefully measuring your hormone levels to make sure you see the changes you're expecting, and to reduce the risk of side effects.
Feminising hormone treatment usually starts with a low dose of oestrogen and antiandrogens. The doses are adjusted based on monitoring of blood hormone levels and the development of characteristics like breasts and body fat redistribution.
Masculinising hormone treatment begins with testosterone therapy, with dosage adjustments based on similar monitoring.
Monitoring Guidance
Spironolactone as a Puberty Blocker: We recommend monitoring testosterone and potassium levels every 3 months.
Spironolactone as an Antiandrogen: We recommend monitoring testosterone and potassium levels every 3 months until they stabilise. Once stable, yearly monitoring is enough.
Cyproterone Acetate as an Antiandrogen: We recommend monitoring testosterone and potassium levels every 3 months until they stabilise. Once stable, yearly monitoring is enough.
Testosterone for Masculinisation: We recommend monitoring haematocrit and testosterone levels every 3 months. After achieving stable testosterone levels, yearly monitoring is enough.
Estradiol for Feminisation: Estradiol levels should be monitored quarterly until stability is achieved. Thereafter, annual testing is recommended.
The GenderGP Commitment
GenderGP stays up-to-date with latest clinical guidelines and research on gender-affirming care. This knowledge, combined with the individualised considerations of blood test results, transition progress, and member preferences, forms the foundation of a responsive and responsible approach to adjusting dosages of gender-affirming medication.